Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398064 | 0.90 | NPC1 (0.38) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398091 | 0.89 | TIPARP (0.38) | CRBNDDB1IKZF3PDE3BPDE3A | |
| SCHEMBL1398056 | 0.88 | CREBBP (0.37) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398095 | 0.87 | CRBN (0.52) | CRBNDDB1IKZF3HTTBRD4 | |
| SCHEMBL1398058 | 0.80 | ADRA2A (0.31) | CRBNDDB1ALDH1A1BRD4KMT2A | |
| SCHEMBL1398052 | 0.80 | MAPT (0.39) | CRBNDDB1IKZF3HTR2CHTR2B | |
| SCHEMBL1398063 | 0.80 | CRBN (0.44) | CRBNDDB1IKZF3HTR2AHTR2C | |
| SCHEMBL1398032 | 0.79 | CRBN (0.44) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL1398069 | 0.79 | CRBN (0.39) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL1398075 | 0.79 | LMNA (0.44) | CRBNDDB1IKZF3HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | claimed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | claimed |
| EP-1957481-B1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | GRUENENTHAL GMBH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | GRUENENTHAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293749-A1 | Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position | TPMT, MALT1, THPO | CRBN 1317/4885DDB1 1517/4885IKZF3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.